Answers are grounded in this paper and cite their sources.
Clinical and experimental evidence suggests that, in Parkinson's disease, the late-occurring fluctuations in response to levodopa therapy are due to progression of the disease rather than to the therapy. Therefore, treatment with carbidopa/levodopa should be started early, because postponement does not provide patients with added benefits but deprives them of the most satisfying period of the therapeutic response.
No takes yet. Share an insight, caveat, or question.
Manfred D. Muenter (1984) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: